Professional Documents
Culture Documents
Slide Library Home Clinical Guidelines > ADA 2016 Cardiovascular Disease (CVD) and Diabetes
<140 mm Hg
Lower target (<130) may be appropriate in certain
individuals*
Treatment targets
<90 mm Hg
Lower target (<80) may be appropriate in certain individuals*
*Younger individuals, people with albuminuria, and/or individuals with hypertension and one or
more additional ASCVD risk factor
Only if the lower target can be achieved without undue treatment burden
Individuals with confirmed office BP >140/90 Prompt initiation and timely subsequent
mm Hg titration of pharmacologic therapy (see
below) in addition to lifestyle changes
http://www.ndei.org/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html 1/5
10/21/2017 Cardiovascular Disease (CVD) & Diabetes Guidelines ADA | NDEI
Lipid Management
Adults not taking a statin Obtain a lipid profile
At diabetes diagnosis, initial medical
evaluation, and every 5 years thereafter
At initiation of statin therapy and
periodically thereafter
Age 40-75 years with diabetes but without Moderate-intensity statin + lifestyle
ASCVD risk factors
Age 40-75 with diabetes and ASCVD risk High-intensity statin + lifestyle
factors
Age >75 with diabetes but without ASCVD risk Moderate- or high-intensity statin + lifestyle
factors†
The intensity of statin therapy may require adjustment based on an individual’s response
*Regardless of age
†Routinely evaluate risk-benefit profile of statin therapy, with down-titration as needed
Statin + fibrate This combination has not been shown to improve ASCVD
outcomes
http://www.ndei.org/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html 2/5
10/21/2017 Cardiovascular Disease (CVD) & Diabetes Guidelines ADA | NDEI
As such, it is not recommended
Statin + fenofibrate may be considered for men with TG ≥204
mg/dL and HDL-C ≤34 mg/dL
Statin + niacin This combination has not been shown to provide additional CV
benefit above statin therapy alone
It may increase the risk for stroke
This combination is not recommended
Statin + PCSK9 inhibitor 36%-59% reductions have been shown with PCSK9 inhibitors on
top of maximal tolerated statin therapy
Combination statin + PCSK9 may be considered as adjunctive
therapy for individuals with diabetes who are at high ASCVD risk
or who are intolerant to a high-intensity statin
Increased risk of incident diabetes with statin use has been reported1,2
May be limited to individuals with diabetes risk factors
Analysis of initial study3: cardiovascular event rate reduction with statins outweighed risk of
incident diabetes
Even for individuals at highest diabetes risk
Aspirin for secondary prevention 75-162 mg/day for individuals with diabetes and a
history of ASCVD
For individuals with ASCVD and a documented aspirin allergy, clopidogrel 75 mg/day should
be used
Dual antiplatelet therapy is reasonable for up to 1 year after ACS
*Includes most men or women with diabetes aged ≥50 yrs with ≥1 add’l major risk factor: family
history of premature ASCVD, hypertension, smoking, dyslipidemia, or albuminuria
Treatment Do not use TZDs, as these agents are associated with heart
failure
http://www.ndei.org/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html 3/5
10/21/2017 Cardiovascular Disease (CVD) & Diabetes Guidelines ADA | NDEI
Click slides to view larger.
All slides available for download in the Slide Library.
1. Rajpathak SN, et al. Diabetes Care. 2009;32:1924-1929. 2. Sattar N, et al. Lancet. 2010;375:735-
742. 3. Ridker PM, et al. Lancet. 2012;380:565-571.
Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and
Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for
approved uses outside of the United States.
January 2016
This content was created by Ashfield Healthcare Communications, and was not associated with
funding via an educational grant or a promotional/commercial interest.
Back to
Clinical Guidelines
http://www.ndei.org/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html 4/5
10/21/2017 Cardiovascular Disease (CVD) & Diabetes Guidelines ADA | NDEI
Home About NDEI Site Map FAQ Contact Us Sponsored by Ashfield Healthcare Communications, Lyndhurst, NJ.
Slide Library Expert Commentary Clinical Guidelines Conference Coverage Case Studies Patient Education Copyright © 2016 Ashfield Healthcare Communications. All rights reserved.
Glossary Product Indications Professional Resources Press Room Calendar of Events CME Opportunities Editorial Policy Advertising Policy Disclaimer Statement Privacy Statement
http://www.ndei.org/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html 5/5